A recent study showed that T - VEC in combination with ipilimumab resulted in an overall response rate of 50 %,
durable response rate of 44 %, and tolerable safety profile in patients with advanced melanoma, said Georgina Long, BSc, PhD, MBBS, of the Melanoma Institute Australia in Sydney.
While the
response rates appear higher than historic series with IL - 2, complete
responses are exceedingly rare, and when they occur, they are not
durable.